Who
Jonathan I. Lieber
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Rallybio; Director, Decoy Therapeutics; Chief Financial Officer, Applied Genetic Technologies; Chief Financial Officer, Ocugen; CFO, Repligen; SVP, CFO and Treasurer, Altus Pharmaceuticals.
In numbers
- Trades disclosed
- 74
- Buys
- 3
- Sells
- 11
- Bought
- $43K
- Sold
- $356K
- Companies
- 6
- Companies where not an officer
- 1
- First trade
- 15 Nov 2006
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $24K3,910 at $6.08 | filing |
| 9 Oct 2026filed 13 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —3,910 at $0.00 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $30K5,000 at $6.08 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Feb 2026filed 23 Feb 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Sold | $3,992789 at $5.06 | filing |
| 23 Feb 2026filed 23 Feb 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Sold | $3,992789 at $5.06 | filing |
| 18 Feb 2026filed 23 Feb 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 18 Feb 2026filed 23 Feb 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | DCOY Decoy Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,500 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 14 Mar 2023filed 16 Mar 2023 | RLYB RallybioBiotechnology | SEC FORM 4 Bought | $26K5,000 at $5.21 | filing |
| 1 Feb 2023filed 1 Feb 2023 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,440 at $0.00 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —202,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —154,700 | filing |
| 21 Aug 2022filed 24 Aug 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code A | —154,700 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | DCOY Decoy TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,12537,500 at $0.19 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)RLYB · dailypolitical.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)RLYB · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Jonathan I. Lieber; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.